Advocacy Archives – Treatment Action Group

image that reads: Introduction: 1/4/6 x24 - a campaign to rally energy, political will & funding to end TB

1/4/6×24 Community Campaign Training Materials

November 11, 2022
Dorrit Walsh

Community engagement and mobilization will be key to winning equitable access to the short-course treatment and prevention regimens at the heart of the 1/4/6x24 Campaign. For everyone to benefit from the scientific progress that made these effective new preventive treatments…

Public Comment Submitted to the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA)

November 10, 2022
Dorrit Walsh

Comment submitted prior to their meeting on November 17, 2022. Comment is in regard to discussion and voting on recommendation related to implementation of the HIV Organ Policy Equity (HOPE) Act of 2013, specifically pertaining to HIV-positive to HIV-positive organ transplantation and pertaining to the following draft recommendation under consideration regarding removal of the statutory “NIH Research Criteria and IRB” requirement.

Cover of November 2022 TAGline: Reads "TAG at 30" and is an illustration of various protest signs. "Free the Vaccine," "Silence = Death," "Cough Up the TB Money," "Stigma Spreads Disease," etc.

TAGline November 2022

November 3, 2022
Dorrit Walsh

This year’s edition of TAGline commemorates TAG’s 30th anniversary, and these articles explore TAG’s work over the years: what we've accomplished, what we've learned, the continuing obstacles to progress, and what comes next.

New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment

August 1, 2022
Dorrit Walsh

We, the undersigned civil society and community-based organizations, welcome the announcement by Unitaid and its partners that they have reached an agreement with Lupin Limited and Macleods Pharmaceuticals to introduce two formulations of rifapentine at competitive prices.

LAT CAB Calls on AbbVie, Licensed Generic Manufacturers of G/P, and the Medicines Patent Pool to Fulfill their Commitment to Make Generic HCV Treatment Widely Available

August 1, 2022
Dorrit Walsh

Four years after the Medicines Patent Pool (MPP) and AbbVie came to agreement on a voluntary license authorizing MPP to sublicense G/P to generic manufacturers to ensure commercialization in low- and middle-income countries, generic G/P is not available anywhere.

cover that reads TB CAB 10-Year Anniversary Evaluation Report 2011-2021, March 2022, by Andrea DeLuca, also has a black and whilte photo montage of people engaged in meetings and demonstrations

TB CAB 10-Year Anniversary Evaluation Report 2011–2021 and Podcast

July 18, 2022
Dorrit Walsh

In 2021, the Global Tuberculosis Community Advisory Board (TB CAB) celebrated its tenth anniversary of advocating for community engagement in research and improved access to TB prevention, treatment, and diagnostic technologies.

Activists Across the World Demand Urgent Action to Improve Access to Lifesaving Tuberculosis (TB) Medicine, Bedaquiline

July 1, 2022
Dorrit Walsh

A new generic version of bedaquiline produced by Macleods Pharmaceuticals in India has cleared the Global Fund’s Expert Review Panel (ERP), an independent group of experts that reviews finished pharmaceutical products and makes recommendations on their use to the Global Fund.

Roundtable on Access to Multi-disease Molecular Diagnostics

June 23, 2022
Dorrit Walsh

On June 2, 2022, Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) hosted a Roundtable on Access to Multi-disease Molecular Diagnostics, which brought together country program representatives, donors, members of civil society, and other global health actors to: Identify…

Lessons Learned from HBCU Responses to the COVID-19 Pandemic

June 9, 2022
Dorrit Walsh

Please join us on June 30 for this free webinar where we discuss the lessons learned from COVID-19 protocols and policies implemented by HBCUs, along with student perspectives that will help inform responses to future pandemics or other public health emergencies.

cover of publication: An Advocate's Introduction to SARS-CoV-2 Rapid Diagnostic Testing, there's a drawing on the cover of a hand holding up two types of COVID rapid tests

Test and Treat COVID-19: An Advocate’s Introduction to SARS-CoV-2 Rapid Diagnostic Testing

June 7, 2022
Dorrit Walsh

All people have the right to know their COVID-19 status and to be able to use that information to protect themselves, their families, and their communities. Rapid antigen tests can be used at home or in informal settings to reliably and quickly detect cases of COVID-19, to guide decisions on interventions such as self-isolation, contact tracing, and antiviral treatment.